BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 31370810)

  • 1. Costs associated with delivering HPV vaccination in the context of the first year demonstration programme in southern Mozambique.
    Alonso S; Cambaco O; Maússe Y; Matsinhe G; Macete E; Menéndez C; Sicuri E; Sevene E; Munguambe K
    BMC Public Health; 2019 Aug; 19(1):1031. PubMed ID: 31370810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.
    Hutubessy R; Levin A; Wang S; Morgan W; Ally M; John T; Broutet N
    BMC Med; 2012 Nov; 10():136. PubMed ID: 23146319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania.
    Quentin W; Terris-Prestholt F; Changalucha J; Soteli S; Edmunds WJ; Hutubessy R; Ross DA; Kapiga S; Hayes R; Watson-Jones D
    BMC Med; 2012 Nov; 10():137. PubMed ID: 23148516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation strategy and cost of Mozambique's HPV vaccine demonstration project.
    Soi C; Babigumira JB; Chilundo B; Muchanga V; Matsinhe L; Gimbel S; Augusto O; Sherr K
    BMC Public Health; 2019 Oct; 19(1):1406. PubMed ID: 31664976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of the cost of human papilloma virus (HPV) vaccine delivery in Zambia.
    Simuyemba MC; Chama-Chiliba CM; Chompolola A; Sinyangwe A; Bchir A; Asiimwe G; Chibwesha C; Masiye F
    BMC Infect Dis; 2024 Apr; 24(1):369. PubMed ID: 38565994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania.
    Hsiao A; Struckmann V; Stephani V; Mmbando D; Changalucha J; Baisley K; Levin A; Morgan W; Hutubessy R; Watson-Jones D; Whitworth H; Quentin W
    Vaccine; 2023 Jan; 41(2):372-379. PubMed ID: 36460537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program.
    Pearson AL; Kvizhinadze G; Wilson N; Smith M; Canfell K; Blakely T
    BMC Infect Dis; 2014 Jun; 14():351. PubMed ID: 24965837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
    Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
    Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
    Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
    BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects.
    Botwright S; Holroyd T; Nanda S; Bloem P; Griffiths UK; Sidibe A; Hutubessy RCW
    PLoS One; 2017; 12(10):e0182663. PubMed ID: 29016596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of human papillomavirus vaccine delivery at district and health facility levels in Zimbabwe: A school-based vaccination program targeting multiple cohorts.
    Hidle A; Brennan T; Garon J; An Q; Loharikar A; Marembo J; Manangazira P; Mejia N; Abimbola T
    Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A67-A76. PubMed ID: 35181152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Geospatial Planning and the Resulting Economic Impact of Human Papillomavirus Vaccine Introduction in Mozambique.
    Haidari LA; Brown ST; Constenla D; Zenkov E; Ferguson M; de Broucker G; Ozawa S; Clark S; Portnoy A; Lee BY
    Sex Transm Dis; 2017 Apr; 44(4):222-226. PubMed ID: 28282648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru.
    Goldie SJ; Levin C; Mosqueira-Lovón NR; Ortendahl J; Kim J; O'Shea M; Diaz Sanchez M; Mendoza Araujo MA
    Rev Panam Salud Publica; 2012 Dec; 32(6):426-34. PubMed ID: 23370186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost and operational context for national human papillomavirus (HPV) vaccine delivery in six low- and middle-income countries.
    Mvundura M; Slavkovsky R; Debellut F; Naddumba T; Bayeh A; Ndiaye C; Anena J; Vodicka E; Diop A; Gamage D; Musanabaganwa C; Tatkan G; Driwale A; Zelalem M; Badiane O; Ginige S; Hamilton E; Sibomana H; Lakew Y; Uwinkindi F; Dhufera A; Ampeire I; Kumar S; Lamontagne DS
    Vaccine; 2023 Nov; 41(49):7435-7443. PubMed ID: 37949752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study.
    Van Minh H; My NTT; Jit M
    BMC Health Serv Res; 2017 May; 17(1):353. PubMed ID: 28506297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.
    Levin CE; Sharma M; Olson Z; Verguet S; Shi JF; Wang SM; Qiao YL; Jamison DT; Kim JJ
    Vaccine; 2015 Jun; 33(24):2830-41. PubMed ID: 25770785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
    Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
    Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of a human papillomavirus vaccination project, Zimbabwe.
    Hidle A; Gwati G; Abimbola T; Pallas SW; Hyde T; Petu A; McFarland D; Manangazira P
    Bull World Health Organ; 2018 Dec; 96(12):834-842. PubMed ID: 30505031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.